AC Immune (ACIU) Investor presentation summary

Strategic focus and differentiation

• Pipeline targets neurodegenerative diseases with active immunotherapies and small molecules, emphasizing precision in toxic protein targeting.

• Technology platforms validated by multiple clinical candidates and partnerships with major pharma companies.

• Over CHF 4.3 billion in potential milestone payments from strategic partnerships.

• Cash reserves of CHF 75.4 million, funding operations into Q4 2027.

• Approximately 120 employees, based in Lausanne, Switzerland, and listed on NASDAQ.

Pipeline and clinical development

• Active immunotherapies include ACI-24 (anti-Abeta), ACI-35 (anti-pTau), and ACI-7104 (anti-a-syn), with multiple candidates in Phase 1–3 trials.

• Intracellular targeting programs focus on Tau, a-synuclein, and NLRP3 inflammasome, with both therapeutic and diagnostic applications.

• Key 2026 milestones: Phase 2 trial results for ACI-24 in Alzheimer's, Phase 2 VacSYn trial in Parkinson's, and Phase 1/1b results for NLRP3 inhibitor.

• Biomarker-driven, adaptive study designs enable dose optimization and early regulatory engagement.

• FDA Fast Track designations for several programs, accelerating development timelines.

Clinical results and safety

• ACI-7104 in early Parkinson's shows strong immunogenicity, 100% responder rate, and favorable safety profile with no significant adverse events.

• ACI-24 Phase 1b/2 study in Alzheimer's and Down syndrome uses biomarker endpoints and adaptive dosing.

• ACI-35 is the only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's, with Phase 2 trial underway.

• NLRP3 inhibitor ACI-19764 demonstrated safety, CSF exposure, and dose-dependent IL-1β inhibition in Phase 1.

• Morphomer small molecules show in vivo efficacy in reducing Tau pathology and neuron loss in preclinical models.